Healthcare Industry News: Alaris
News Release - November 16, 2010
Neoprobe Names Executive Vice President, Chief Development OfficerMark Pykett Tapped to Lead Efforts Supporting Lymphoseek® Development, Identifying Corporate Partners for RIGScan™ Program and Expanding Investor Outreach
DUBLIN, Ohio--(Healthcare Sales & Marketing Network)-- Neoprobe Corporation (OTCBB:NEOP.ob ), a diversified developer of innovative oncology surgical and diagnostic products, announced today that Dr. Mark Pykett has joined the company as Executive Vice President and Chief Development Officer. Pykett, 46, brings to Neoprobe more than 15 years of experience guiding public and private biotechnology companies in successful product and business development, partnering and investor relations efforts.
“Mark has an outstanding mix of knowledge and experience leading successful pharmaceutical development efforts to help companies maximize portfolio potential and capitalize on growth opportunities,” said David Bupp, President and Chief Executive Officer of Neoprobe. “In leading our corporate development efforts, Mark will leverage those experiences to help us drive Lymphoseek to the approval finish line and beyond as well as identify potential partners that will help us successfully navigate the development stages for our RIGScan program. In addition, Mark’s previous extensive interactions with investors and analysts will assist Neoprobe in expanding its investor relations activities and enhancing the Company’s visibility with key stakeholders.”
Prior to joining Neoprobe, Pykett held senior leadership positions at a number of biotechnology and diagnostics companies where he was charged with product and corporate development efforts. As CEO and Founder of TAlaris Advisors, a strategic drug development company serving the biotech industry, Pykett led portfolio management efforts focusing on milestone acceleration and capital efficiency for clients in a range of therapeutic areas, including oncology, dermatology and transplantation. As President and Chief Operating Officer of Alseres Pharmaceuticals, Dr. Pykett oversaw development efforts for the company’s neurology therapeutics and diagnostics products and helped manage the company’s fund-raising efforts in public capital markets. Prior to Alseres, Mark co-founded and led three development-stage biotechnology companies – Cygenics, Oramax and Cytomatrix – where he was responsible for overall management, capital formation and development efforts. Pykett has also served as an adjunct lecturer in cancer biology at Harvard University’s School of Public Health and served on Northeastern University’s Center for Enterprise Growth Corporate Advisory Board. Pykett earned a BA from Amherst College, a PhD and VMD from the University of Pennsylvania and an MBA from Northeastern University.
“I am honored to join the strong management team at Neoprobe during a very exciting phase of the company’s growth cycle. The opportunities that lie ahead for our success in delivering novel diagnostic and therapeutic approaches for the medical community are very attractive,” said Mark Pykett, Neoprobe’s Executive Vice President and Chief Development Officer. “I look forward to helping the company achieve its business objectives, open new avenues for future growth and success in the years ahead, and to spearheading communication of our compelling product initiatives to our stakeholders and partners.”
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.